Patient-reported problematic symptoms in an ALS treatment trial. - Wikidata - wikimedia - TriplyDB

Patient-reported problematic symptoms in an ALS treatment trial.

Patient-reported problematic symptoms in an ALS treatment trial.

http://www.wikidata.org/entity/Q37164599

about

Extra-motor abnormalities in amyotrophic lateral sclerosis: another layer of heterogeneity.Supportive care needs of patients with amyotrophic lateral sclerosis/motor neuron disease and their caregivers: A scoping review.Improving symptom management for people with amyotrophic lateral sclerosis.Symptom management in amyotrophic lateral sclerosis: We can do better.

P2860

Q39041271-504C8D45-5239-4A73-8D67-AE8396C9B1A6 Q39417573-F71B0EC3-C95F-4B7D-8B5B-BED393BA1ACB Q46604820-208E233C-721F-4FBB-A7EA-993D8C550C64 Q47102766-E2B70CAE-49D0-4D1B-848D-EF3910BD4295

P2860

Patient-reported problematic symptoms in an ALS treatment trial.

http://www.wikidata.org/entity/Q37164599

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 29 January 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Patient-reported problematic symptoms in an ALS treatment trial.

@en

Patient-reported problematic symptoms in an ALS treatment trial.

@nl

type

label

Patient-reported problematic symptoms in an ALS treatment trial.

@en

Patient-reported problematic symptoms in an ALS treatment trial.

@nl

prefLabel

Patient-reported problematic symptoms in an ALS treatment trial.

@en

Patient-reported problematic symptoms in an ALS treatment trial.

@nl

P1433

Q37164599-921C0D1F-2CBF-4451-8563-1AD4B0E93BF0

P1476

Q37164599-FFA2A06B-BC6A-4048-80A7-D08013FD1844

P2093

Q37164599-04F71D51-9652-4663-8698-1A08CA059A86

Q37164599-13B3A3BE-9B1D-458F-8594-473D4C7836F5

Q37164599-279857CC-A3C5-4AE2-81D7-E189BD425EDD

Q37164599-3B0FBCAF-FFF6-4F31-B5BB-38E359502593

Q37164599-5A491DF1-4DE1-4E04-93F6-F5DA3EA21AE4

P2860

Q37164599-0B64BDBA-3368-4B05-81CE-EBB12593580C

Q37164599-1CA7DAF0-1FEC-40FD-97AA-EF8C9D483DF1

Q37164599-1F6E0CE1-F423-4A95-8685-14929D523EA3

Q37164599-20503AF3-9EF9-4451-80F4-5BDFB383F3A0

Q37164599-23ECA355-712B-41C7-BDC6-2908669556BB

Q37164599-2437FA62-FF06-4E69-AC6F-271FBFBD9A01

Q37164599-2A9836C1-65B0-4E6B-86FF-A2E2B0E7C893

Q37164599-318AD8F6-D899-4CFB-A81F-0969691D6C3B

Q37164599-323E89A3-7529-49E5-90E1-81BBB153E1CB

Q37164599-32A20EC1-7534-401F-A44A-B7FD0F5EBFE4

P304

Q37164599-6CBD7650-FF4F-4467-951E-8BF85413B4E5

P31

Q37164599-2F653D3A-2353-4A15-B21C-9CA945D4F722

P356

Q37164599-4F28A75E-A5B7-46A1-8008-30D2167DC695

P433

Q37164599-B164C2D4-1E46-4D77-8CC1-EB163E63A1BA

P478

Q37164599-BDDCF839-F8A8-4D54-9C7E-893529F8EB9B

P50

Q37164599-6BCAD3D3-3036-454B-9C94-C55AB55CFE7E

P577

Q37164599-5FEAE865-40F8-4828-A91D-0ACBA3877938

P5875

Q37164599-2009BD28-8144-42BA-985F-01040E082CA2

P698

Q37164599-05C59466-2E79-46D1-9F10-5EF7D0C535D8

P921

Q37164599-2F7FFBD4-B928-4B31-9239-B8E51A539684

P932

Q37164599-6292AB70-167C-424D-BC26-79C1B3094977

P356

21678421.2015.1131831

P1433

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration

P1476

Patient-reported problematic symptoms in an ALS treatment trial

@en

P2093

Divisha Raheja

http://www.w3.org/2001/XMLSchema#string

Erik Lehman

http://www.w3.org/2001/XMLSchema#string

Helen E Stephens

http://www.w3.org/2001/XMLSchema#string

Susan Walsh

http://www.w3.org/2001/XMLSchema#string

Zachary Simmons

http://www.w3.org/2001/XMLSchema#string

P2860

Treatment for sialorrhea (excessive saliva) in people with motor neuron disease/amyotrophic lateral sclerosis

Quality improvement in neurology: amyotrophic lateral sclerosis quality measures: report of the quality measurement and reporting subcommittee of the American Academy of Neurology

Seizure localization using ictal phase-locked high gamma: A retrospective surgical outcome study.

El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis

Characteristics of pain in amyotrophic lateral sclerosis.

Measuring quality of life: Is quality of life determined by expectations or experience?

Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial.

Practice parameter update: the care of the patient with amyotrophic lateral sclerosis: multidisciplinary care, symptom management, and cognitive/behavioral impairment (an evidence-based review): report of the Quality Standards Subcommittee of the Am

Injections of botulinum toxin A into the salivary glands improve sialorrhoea in amyotrophic lateral sclerosis

Effect of a multidisciplinary amyotrophic lateral sclerosis (ALS) clinic on ALS survival: a population based study, 1996-2000.

P304

198-205

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/21678421.2015.1131831

http://www.w3.org/2001/XMLSchema#string

P433

3-4

http://www.w3.org/2001/XMLSchema#string

P478

17

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

292305031

http://www.w3.org/2001/XMLSchema#string

P698

26824413

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

4979603

http://www.w3.org/2001/XMLSchema#string